TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03054714

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: catheter replacement
Description: catheter removal and delayed replacement, versus exchange over a guidewire

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: catheter replacement
Description: catheter removal and delayed replacement, versus exchange over a guidewire
Study: NCT03249402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl Estradiol + Levonorgestrel
Description: Participants will receive one OC tablet containing EE 0.03 mg and LN 0.15 mg once daily on Days 1 to 21 in cycles 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922
Description: Participants will receive 40 mg of JNJ-42847922 once daily on Days 14 to 21 in cycle 2.
Study: NCT00692887

Intervention type: DEVICE
Intervention: PHP - Preferential Hyperacuity Perimeter (Foresee)
Description: computerized test
Study: NCT04016857

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIPC
Description: 4 cycles of 5-min inflation to 200 mmHg followed by 5-min deflation of arm cuff

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: deflated cuff placed on the left arm for 40 min
Study: NCT03717363

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Training programme
Description: Training program in the primary care center supervised by a physiotherapist. The duration is two months and the frequency of sessions 3 times / week. Each session lasts 60 minutes.(30 minutes of aerobic exercise and 15 minutes of strength exercise).
Study: NCT01058239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given intravenously on days 1, 4, 8 and 11 of every cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: given intravenously on days 1, 8 and 15 of Cycle 1 and on Day 1 of subsequent cycles
Study: NCT03557125

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: QL Block
Description: If the subject has been randomized to the block group, a subcutaneous lidocaine skin wheel placed will be placed followed by a quadratus lumborum regional block with 40 ml, 0.25% ropivacaine deposited deep to the transversus abdominus apnoneurosis and superficial to the fascia transversalis with direct ultrasound guidance. Local anesthetic will be injected in 5 ml aliquots with aspiration for blood performed before and after the injection of each aliquot. Local anesthetic injection will also be observed with real time ultrasound guidance.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Skin Wheel
Description: The skin will be cleaned with chlorhexidine. If the subject has been randomized to the no block group, a subcutaneous saline skin wheel will be placed and the procedure would end at this point.
Study: NCT03733938

Intervention type: OTHER
Intervention: endodontic microsurgery
Description: teeth with failed root canal treatment will be treated by endodontic microsurgery
Study: NCT01964183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolterodine
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: Oral
Study: NCT05086848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposome、5-fluorouracil、Leucovorin
Description: Irinotecan liposome、5-fluorouracil、Leucovorin
Study: NCT01546883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (Pradaxa)
Description: 150mg bid or 75mg bid for a period of one year
Study: NCT00746083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Challenge!
Description: Each adolescent in the intervention group received 12 lessons administered in adolescent's home or community by a personal trainer (a college-aged mentor). The lessons focused on behavior change relating to diet and physical activity and was based on social cognitive theory. At the end of each lesson the adolescent set a behavior change goal for themselves. The adolescents were taught how to track their goals and they discussed thir ability/inability to meet their goals at each meeting with their personal trainer.
Study: NCT03717363

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational talk
Description: An educational talk given by the nurse and the physiotherapist about the components of a cardiosaluble lifestyle.
Study: NCT01723345

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omega 3
Description: 3 gram omega 3 (400mg EPA and 200mg DHA) 12hours before PCI
Study: NCT02230800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocovid SupraBio plus pentoxifylline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebos
Study: NCT03404115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reproxalap Ophthalmic Solution (0.25%)
Description: Reproxalap Ophthalmic Solution (0.25%) administered for approximately twelve weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reproxalap Ophthalmic Solution (0.1%)
Description: Reproxalap Ophthalmic Solution (0.1%) administered for approximately twelve weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Ophthalmic Solution
Description: Vehicle Ophthalmic Solution administered for approximately twelve weeks.
Study: NCT01015209

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Chitosan- N- Acetylcysteine eye drops
Description: Cohort 1: 1 drop once Cohort 2: 2 drops daily for 5 days

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Chitosan- N- Acetylcysteine eye drops
Description: Cohort 1: 1 drop once Cohort 2: 2 drops daily for 5 days
Study: NCT00129428

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UVB Irradiation
Description: A dose of up to 320 mJ/cm2 from a UVB irradiation device will be administered at maximum 5 times per week for 16 weeks.
Study: NCT04118829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: For group 1 the PER dose will be administered 2-14 hours prior to sample collection. They will be administered a single dose of PER (8 mg, 12 mg or 16 mg) followed by 4 mg/day for 14 days starting on postoperative day 1 (if continued prophylaxis with PER is needed).~It is anticipated that patients in group 2 will have the daily dose of PER in these individuals will range from 4 - 12 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: For group 1 the PER dose will be administered 2-14 hours prior to sample collection. They will be administered a single dose of PER (8 mg, 12 mg or 16 mg) followed by 4 mg/day for 14 days starting on postoperative day 1 (if continued prophylaxis with PER is needed).~It is anticipated that patients in group 2 will have the daily dose of PER in these individuals will range from 4 - 12 mg/day.
Study: NCT03201640

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: slideshow
Description: Participants will be shown a slideshow showing a child being prepared for surgery

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: virtual
Description: Participants will be shown an immersive virtual reality preparation for surgery
Study: NCT03578250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic Training
Description: Upper extremity training on a robotic device with or without error augmentation force field.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic Training
Description: Upper extremity training on a robotic device with or without error augmentation force field.
Study: NCT03680885

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine gel
Description: Lidocaine gel 5%, PEG with FD\&C Blue No.1 (Brilliant Blue FCF)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine gel
Description: Lidocaine gel 5%, PEG with FD\&C Blue No.1 (Brilliant Blue FCF)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: PEG with FD\&C Blue No.1 (Brilliant Blue FCF)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: PEG with FD\&C Blue No.1 (Brilliant Blue FCF)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injected lidocaine
Description: Standard FDA-approved dental injectable lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injected lidocaine
Description: Standard FDA-approved dental injectable lidocaine
Study: NCT02539186

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: platelet rich plasma
Description: Sono-guided injection with 3cc platelet rich plasma between carpal tunnel and median nerve

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: splint
Study: NCT00952705

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Q/LAIV-BFS (MEDI8662)
Description: A single dose of Q/LAIV-BFS delivered using the BFS delivery system (0.2 mL) on Day 0.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluMist/B/Yamagata
Description: FluMist/B/Yamagata - 0.2 mL dose at Day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluMist/B/Victoria
Description: FluMist/B/Victoria - 0.2 mL dose at Day 0
Study: NCT01106989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heated lidocaine/tetracaine patch
Description: Patients will be instructed to apply one heated lidocaine 70 mg and tetracaine 70 mg topical patch directly to each trigger point identified at the Screening/Baseline Visit (up to 3 trigger points). Patches will be administered for 4 hours, 2 times per day (total of 8 hours for each trigger point per day).
Study: NCT03344341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Starting dose of dapagliflozin is 5 mg once daily, taken orally in the morning, before or after breakfast. From the third week,the dose can be increased to 10 mg once daily, and last to the end of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: Acarbose was started from 50 mg once a day at dinner during the first week and titrated up to 50 mg twice a day at lunch and dinner in the second week, 50 mg three times a day at three meals in the third week, and 100 mg three times a day till the end of the study.
Study: NCT03835078

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: methafilcon A contact lenses
Description: Bilateral daily wear of methafilcon A contact lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fanfilcon A contact lenses
Description: Bilateral daily wear of fanfilcon A contact lenses
Study: NCT02684968

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colorectal surgery

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Colorectal surgery
Study: NCT01155557

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Specific Strength Training
Description: 10 weeks of progressive specific strength training for neck and shoulder muscles.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Counseling
Description: 10 weeks of counseling by nurse and physiotherapist in lifestyle changes.
Study: NCT02532088

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oil Palm Phenolics
Description: Palm fruit derived phenolics compound

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03089060

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silicone Finger cap
Description: Treatment with silicone finger cap

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silicone Finger cap
Description: Treatment with silicone finger cap

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Film Dressing
Description: Treatment with conventional film dressing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Film Dressing
Description: Treatment with conventional film dressing
Study: NCT02986074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paresthesia mapping lead evaluation first
Description: Subjects will evaluate the clinical efficacy of stimulation delivered using the lead implanted using paresthesia mapping in the first part of the SCS trial and using the lead implanted using anatomical midline placement in the second part of the SCS trial

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anatomical midline lead evaluation first
Description: Subjects will evaluate the clinical efficacy of stimulation delivered using the lead implanted using anatomical midline in the first part of the SCS trial and using the lead implanted using paresthesia mapping placement in the second part of the SCS trial
Study: NCT00641693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: 16mg Nasal Spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: 32mg Nasal Spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: 64mg Nasal Spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00660803

Intervention type: DRUG
Intervention: Fulvestrant
Study: NCT01055145

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levofloxacin, moxifloxacin
Description: Levofloxacin 750mg po per day for 3 months vs. Moxifloxacin 400mg po per day for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levofloxacin, moxifloxacin
Description: Levofloxacin 750mg po per day for 3 months vs. Moxifloxacin 400mg po per day for 3 months
Study: NCT03187509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torsemide
Description: These subjects who are randomized to a weight-based torsemide regimen will be instructed via phone encounters three times per week to take an individualized dose of torsemide based on their current weight and symptoms. These subjects will have a follow-up study appointment at week 5 for a final weight and blood work to assess kidney function, electrolytes and brain-natriuretic peptide levels.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Outpatient Heart Failure Management
Description: Those subjects randomized to standard outpatient management group will be prescribed a daily fixed dose of a loop diuretic upon discharge from the hospital. These subjects will have a follow-up appointment within one week of discharge where all medications including loop diuretic type, dose and frequency will be managed at the discretion of the subject's physician. These subjects will also have a follow-up study appointment at week 5 for a final weight and blood work to assess kidney function, electrolytes and brain-natriuretic peptide levels.
Study: NCT03015493

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural mobilization combined with traction
Description: Neural mobilization techniques combined with cervical traction for the cervical nerve roots

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traction
Description: Traction techniques for the cervical spine
Study: NCT02886130

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Monitoring of supplementation (e.g., compliance, subject blindness), diet (to control dietary choline ingestion), training volume and adverse effects will be performed on a weekly basis to ensure maximal control of confounding factors as well as the safety of volunteers during the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Monitoring of supplementation (e.g., compliance, subject blindness), diet (to control dietary choline ingestion), training volume and adverse effects will be performed on a weekly basis to ensure maximal control of confounding factors as well as the safety of volunteers during the study.
Study: NCT01944020

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: use of CPAP each night for 2 months
Study: NCT02422329

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Participants complete questionnaires at baseline and after intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Participants complete questionnaires at baseline and after intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: Participants watch a 3-minute educational video describing symptoms of constipation and importance of regular bowel movements.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fact Sheet
Description: Participants read educational material describing symptoms of constipation and importance of regular bowel movements.
Study: NCT03717363

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational talk
Description: An educational talk given by the nurse and the physiotherapist about the components of a cardiosaluble lifestyle.
Study: NCT00525408

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mycobacterium w.
Description: Immunomodulator
Study: NCT02835586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered intra-arterially through an irrigating catheter to treat a diseased segment of superficial femoral artery and/or popliteal artery after stenting. Dosing will be based on the lesion surface area and will be calculated using the following formula : 22/7 x diameter (mm) x length (mm) x 3 µg/mm3
Study: NCT00560508

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramipexole Immediate Release
Description: titrated as individually needed (0.25 mg - 4.5 mg daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole Extended Release
Description: titration as individually needed (0.375 mg -4.5 mg daily)
Study: NCT03963596

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal injection
Description: Intravitreal injection to the regimen pro re nata.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal injection
Description: Intravitreal injection to the regimen pro re nata.
Study: NCT01354223

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stenfilcon A contact lens
Description: Randomized to stenfilcon A contact lens worn in a daily wear, daily disposable mode

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ocufilcon B contact lens
Description: Daily disposable contact lens worn in a daily wear, daily disposable mode
Study: NCT01400009

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D (Cholecalciferol )
Description: 10,000 IU tablets. 50,000 initial dose, followed by weekly doses of 10,000 IU
Study: NCT00525408

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Chemotherapeutic agent
Study: NCT04721574

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Philips EnergyUp Energy light HF3418/01
Description: high brightness LED light box

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Philips EnergyUp Energy light HF3418/01 with filter
Description: high brightness LED light box with filters that reduced lamp output to less than 50 lux
Study: NCT00145522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17ß-Estradiol/Dydrogesterone
Description: 1/5 mg/day for 12 cycles of 28 days
Study: NCT01400009

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard Placebo made of Lactose 100 mg
Study: NCT01490034

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metabolic effects of consuming energy dense beverages
Description: Consumption of energy dense beverages for 2 weeks and monitoring physiological responses

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: energy dense solid food
Description: Effects of consuming energy dense solid food for two weeks on physiological responses
Study: NCT00145522

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tibolone
Description: 2,5 mg/day for 12 cycles of 28 days
Study: NCT03690531

Intervention type: DEVICE
Intervention: Take-Pause virtual reality
Description: Take-Pause virtual reality simulation lasting 3 minutes shown through a virtual reality goggle, headset and iPhone.

Intervention type: DEVICE
Intervention: Passive Distraction
Description: Standard or passive distraction technique, lasting 5 minutes.
Study: NCT04276571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: exergames with GRAIL virtual immersive reality environment
Description: The participants will perform exergames on GRAIL immersive virtual reality to improve balance (e.g. load shifts, exercises with adaptations to motor perturbations). GRAIL can provide proprioceptive and visual feedback to participants.
Study: NCT01490034

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Energy dilute beverages
Description: Effects of consuming energy dilute beverages for two weeks on physiological responses.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Energy dilute solid food
Description: Effects of consuming energy dilute solid food for two weeks on physiological responses
Study: NCT00577369

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane Levels
Description: The subject's participation will take place over one surgical procedure. It will begin with the first blood collection and end with either the second blood draw or the end of the procedure.
Study: NCT03657836

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sublimated mare milk supplement
Description: The dietary supplement consisting of sublimated mare milk packed in single-dose sachet.

Intervention type: DRUG
Group type: OTHER
Intervention: Standard antibiotic therapy
Description: Patients will be given standard therapy antibiotics cefuroxime and ceftriaxone for up to 7 days period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard antibiotic therapy
Description: Patients will be given standard therapy antibiotics cefuroxime and ceftriaxone for up to 7 days period.
Study: NCT02385006

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample
Study: NCT01534962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Oral administration, BID; for a maximum of 112 days.
Study: NCT00412581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg by mouth daily for 2 weeks, followed by 1 week of rest.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: 600 mg/m\^2 intravenously on Day 1 of every study cycle.